PO49 | PROPHYLACTIC ANTICOAGULATION DECISIONS IN HIGH-RISK PATIENTS RECEIVING CANCER-DIRECTED THERAPY: ANALYSIS OF THE VERMONT METHOD
J. Barker1, K. Libby1, C. Holmes2, K. Martin2 | 1University of Vermont Health System; 2Department of Medicine, University of Vermont, Burlington, VT, USA
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Introduction. Validated scoring tools, such as the Khorana risk score and Protecht score, identify patients starting cancer-directed therapy with the highest VTE risk. Despite guideline recommendations for prophylactic anticoagulation for patients at high risk of VTE, less than 5% of patients receive VTE education and guideline-directed VTE prophylaxis. The Vermont Model is a clinical program dedicated to addressing VTE prevention in ambulatory cancer patients starting systemic therapy, including nurse-driven risk assessment for all patients and referral to consult a thrombosis specialist for anticoagulation discussion for high-risk patients. While the Vermont Model successfully improved rates of anticoagulation for high-risk patients, we still do not understand why high-risk patients did not start anticoagulation.
Aim. We aimed to determine the proportion of high-risk patients who received prophylactic anticoagulation and the reasons why we did not start anticoagulation.
Methods. In this retrospective observational study, we manually reviewed charts of high-risk patients, defined as having a Khorana or Protecht Score of 3 or higher seen in the Vermont Model between 2018-2023. We categorized reasons that anticoagulation was not recommended into 8 distinct categories. We used descriptive statistics and logistic regression to test associations between no anticoagulation and clinical characteristics.
Results. Of 284 high-risk patients, clinicians started 144 (50.7%) on anticoagulation and did not start 140 (49.1%). Of the 140 patients not started on AC, 98 (72%) consulted a healthcare provider other than a thrombosis specialist. Out of those 98, 31 (22.3%) had no referral to a thrombosis specialist, 23 (16.6%) were already on anticoagulation, and 20 (14.4%) clinically declined and either transitioned to hospice or died prior to consultation. Of the 42 out of 140 who consulted thrombosis specialists and were not started on anticoagulation, 16 (39.0%) had concomitant/interacting medications and 15 (36.6%) were deemed to have a high bleeding risk. Neither tumor type (p=0.09) nor type of treatment (0.56) was associated with starting anticoagulation.
Conclusions. When patients in the Vermont Model consulted a thrombosis specialist, 78.7% started anticoagulation. Ensuring expedited access to discuss primary prophylaxis may increase anticoagulation for high-risk patients starting cancer-directed therapy.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Società Italiana di Emostasi e Trombosi, PO21 | PSYCHOLOGICAL IMPACT OF CANCER-ASSOCIATED THROMBOSIS: DUAL BURDEN AND IMPLICATIONS FOR QUALITY OF LIFE AND INTEGRATED PATIENT-CENTERED CARE , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO45 | KHORANA RISK SCORE AND GENOMIC PROFILING FOR PREDICTION OF VENOUS THROMBOEMBOLISM IN OVARIAN CANCER , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO04 | FIBRIN CLOT SHIELDS PROMOTE CLONAL SELECTION IN CANCER CELLS: PROCOAGULANT ACTIVITY AND SURVIVAL OF CLOT-EMBEDDED CELLS. A NOVEL TUMOR MICROENVIRONMENT MODEL , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, OC10 | FROM DESIGN TO CLINICAL PHASE 3 IN ONCOLOGY: CD13-TARGETED TISSUE FACTOR AND TUMOR INFARCTION , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO24 | WE ARE JUGGLING MANY POSSIBILITIES: HEALTHCARE PROFESSIONALS’ EXPERIENCES AND PERSPECTIVES ON INTERPRETATION OF PULMONARY EMBOLISM SIGNS AND SYMPTOMS IN PATIENTS WITH LUNG CANCER , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO29 | CANADIAN INSIGHTS INTO THE MANAGEMENT OF BREAKTHROUGH THROMBOSIS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO61 | RISK FACTORS FOR INTRACRANIAL HEMORRHAGE: AN UMBRELLA REVIEW TO INFORM MACHINE LEARNING PREDICTION MODELS IN GLIOMA PATIENTS RECEIVING ANTICOAGULATION , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO39 | RISK OF VENOUS THROMBOEMBOLISM ASSOCIATED WITH PERIPHERALLY INSERTED CENTRAL CATHETERS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY: A REAL-WORLD SINGLE-CENTRE EXPERIENCE , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO41 | VENOUS THROMBOEMBOLISM IN PERIPHERAL BLOOD STEM CELL COLLECTION. A SINGLE CENTER EXPERIENCE , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
